Life Biosciences says three glaucoma patients received cellular reprogramming drug injection with no serious adverse events
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Life Biosciences said on Wednesday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events reported. The company is developing the reprogramming approach, which aims to restore cellular function by resetting cells to a younger state, as a potential treatment for glaucoma. Further details of the study update were available only to STAT+ subscribers.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu